BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR422459 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR422459\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT01736592-5247@assetmemo.bio
DTSTAMP:20261121T005451Z
DTSTART;VALUE=DATE:20330829
DTEND;VALUE=DATE:20330830
SUMMARY:SAR422459: Phase 2 readout est. (NCT01736592)
DESCRIPTION:SAR422459\, phase 2.\nStudy: Phase I/II Follow-up Study of SAR4
 22459 in Patients With Stargardt's Macular Degeneration\nEstimated primary
  completion: 29 August 2033. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sar422459#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT01736592
URL:https://assetmemo.bio/drug/sar422459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
